Evidence map›Paper›PMID 35751684›Full record

ArticleJournal of cancer research and clinical oncology2023

Expression pattern and prognostic potential of histamine receptors in epithelial ovarian cancer.

Fabian B T Kraus, Nicole E Topalov, E Deuster, I Hysenaj, D Mayr, A Chelariu-Raicu, S Beyer, T Kolben, A Burges, S Mahner and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Diagnosis-dependent metabolic reprogramming of follicular fluid.Reproductive biology and endocrinology : RB&E · 2026
    Article
  2. Histamine HInflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
    Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Fabian B T KrausDepartment of Gynecology and Obstetrics, University Hospital, LMU Munich, Munich, Germany. Fabian.Kraus@med.uni-muenchen.de.
Nicole E TopalovDepartment of Gynecology and Obstetrics, University Hospital, LMU Munich, Munich, Germany.
E DeusterDepartment of Gynecology and Obstetrics, University Hospital, LMU Munich, Munich, Germany.
I HysenajDepartment of Gynecology and Obstetrics, University Hospital, LMU Munich, Munich, Germany.
D MayrInstitute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany.
A Chelariu-RaicuDepartment of Gynecology and Obstetrics, University Hospital, LMU Munich, Munich, Germany.
S BeyerDepartment of Gynecology and Obstetrics, University Hospital, LMU Munich, Munich, Germany.
T KolbenDepartment of Gynecology and Obstetrics, University Hospital, LMU Munich, Munich, Germany.
A BurgesDepartment of Gynecology and Obstetrics, University Hospital, LMU Munich, Munich, Germany.
S MahnerDepartment of Gynecology and Obstetrics, University Hospital, LMU Munich, Munich, Germany.
F TrillschDepartment of Gynecology and Obstetrics, University Hospital, LMU Munich, Munich, Germany.
U JeschkeDepartment of Gynecology and Obstetrics, University Hospital, LMU Munich, Munich, Germany.
B CzogallaDepartment of Gynecology and Obstetrics, University Hospital, LMU Munich, Munich, Germany.
Ludwig-Maximilians-Universität München · DELMU Klinikum · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeDespite recent advances in the treatment of ovarian cancer (OC), long-term remissions remain scarce. For a targeted approach, prognostic markers are indispensable for predicting survival and treatment response. Given their association with multiple hallmarks of cancer, histamine receptors (HR) are emerging as promising candidates. Here, we investigate their expression pattern and prognostic value in OC.

methodsSpecimens of 156 epithelial OC patients were collected during cytoreductive surgery at the Department of Obstetrics and Gynecology, LMU, between 1990 and 2002 and combined in a tissue microarray. Immunohistochemical staining of the HR H1, H2, H3 and H4 was quantified by an immunoreactive score and linked with clinico-pathological data by Spearman's correlation. Via ROC curve analysis, optimal cut-off values for potential prognostic markers were defined. Overall survival (OS) was visualized in Kaplan-Maier curves and significances determined by log-rank testing. A Cox regression model was applied for multivariate analysis.

resultsHR H3 and H4 expression was restricted to the cytosol of OC cells, while H1 was also present in the nucleus. A significant association between HR H1, H3 and H4 expression with several clinico-pathological parameters was revealed. In addition, HR H1 and H3 expression correlated positively, HR H4 expression negatively with OS. In addition, HR H3 was identified as independent prognostic marker for OS. HR H2 expression had no prognostic value.

conclusionsHR H1, H3 and H4 could serve as potential predictors for OS of OC patients. Further research is warranted to elucidate their pathophysiologic role and their predictive and therapeutic potential in OC.

Indexed as

Ovarian NeoplasmsReceptors, HistamineCarcinoma, Ovarian EpithelialFemaleHumansPrognosisReceptors, HistamineHistamine receptorsOvarian cancerPersonalized medicineTumor microenvironment

Identifiers

PMID35751684
PMCPMC10129941
OpenAlexW4283465184

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.